Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Net Margin (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Net Margin for 5 consecutive years, with 243.13% as the latest value for Q3 2025.

  • Quarterly Net Margin rose 614844.0% to 243.13% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 1136.25% through Dec 2025, down 48463.0% year-over-year, with the annual reading at 1136.25% for FY2025, 48463.0% down from the prior year.
  • Net Margin for Q3 2025 was 243.13% at Janux Therapeutics, up from 6391.57% in the prior quarter.
  • The five-year high for Net Margin was 66.98% in Q2 2024, with the low at 6391.57% in Q3 2024.
  • Average Net Margin over 5 years is 1126.13%, with a median of 837.06% recorded in 2021.
  • The sharpest move saw Net Margin plummeted -593198bps in 2024, then skyrocketed 614844bps in 2025.
  • Over 5 years, Net Margin stood at 830.2% in 2021, then soared by 32bps to 564.67% in 2022, then rose by 15bps to 477.77% in 2023, then plummeted by -1238bps to 6391.57% in 2024, then skyrocketed by 96bps to 243.13% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 243.13%, 6391.57%, and 66.98% for Q3 2025, Q3 2024, and Q2 2024 respectively.